tetano
Editor, Senior Moderator
Inflamm Res
. 2022 Jul 24.
doi: 10.1007/s00011-022-01619-6. Online ahead of print.
Targeting ACE2 as a potential prophylactic strategy against COVID-19-induced exacerbation of chronic kidney disease
Itsuro Kazama[SUP] 1 [/SUP]
Affiliations
Abstract
Patients with chronic kidney disease (CKD) are at higher risk for severe coronavirus disease 2019 (COVID-19). Such patients are more likely to develop "COVID-19-induced acute kidney injury (AKI)", which exacerbates the pre-existing CKD and increases the mortality rate of the patients. COVID-19-induced AKI is pathologically characterized by acute tubular necrosis and the interstitial infiltration of proinflammatory leukocytes. In our rat model with advanced CKD, immunohistochemistry for angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2) demonstrated their strong expression in the cytoplasm of damaged proximal tubular cells and the infiltrating leukocytes within the cortical interstitium, which overlapped with the lesions of COVID-19-induced AKI. Since ACE2 and TMPRSS2 are enzymes that facilitate the viral entry into the cells and trigger the onset of cytokine storm, the renal distribution of these proteins in advanced CKD was thought to be responsible for the development of COVID-19-induced AKI. Concerning such mechanisms, the pharmacological blockade of ACE2 or the use of soluble forms of the ACE2 protein may halt the entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into host cells. This would protect against the COVID-19-induced exacerbation of pre-existing CKD by preventing the development of AKI.
Keywords: Angiotensin-converting enzyme 2 (ACE2); COVID-19-induced acute kidney injury (AKI); Chronic kidney disease (CKD); Transmembrane protease serine 2 (TMPRSS2).
. 2022 Jul 24.
doi: 10.1007/s00011-022-01619-6. Online ahead of print.
Targeting ACE2 as a potential prophylactic strategy against COVID-19-induced exacerbation of chronic kidney disease
Itsuro Kazama[SUP] 1 [/SUP]
Affiliations
- PMID: 35871404
- DOI: 10.1007/s00011-022-01619-6
Abstract
Patients with chronic kidney disease (CKD) are at higher risk for severe coronavirus disease 2019 (COVID-19). Such patients are more likely to develop "COVID-19-induced acute kidney injury (AKI)", which exacerbates the pre-existing CKD and increases the mortality rate of the patients. COVID-19-induced AKI is pathologically characterized by acute tubular necrosis and the interstitial infiltration of proinflammatory leukocytes. In our rat model with advanced CKD, immunohistochemistry for angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2) demonstrated their strong expression in the cytoplasm of damaged proximal tubular cells and the infiltrating leukocytes within the cortical interstitium, which overlapped with the lesions of COVID-19-induced AKI. Since ACE2 and TMPRSS2 are enzymes that facilitate the viral entry into the cells and trigger the onset of cytokine storm, the renal distribution of these proteins in advanced CKD was thought to be responsible for the development of COVID-19-induced AKI. Concerning such mechanisms, the pharmacological blockade of ACE2 or the use of soluble forms of the ACE2 protein may halt the entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into host cells. This would protect against the COVID-19-induced exacerbation of pre-existing CKD by preventing the development of AKI.
Keywords: Angiotensin-converting enzyme 2 (ACE2); COVID-19-induced acute kidney injury (AKI); Chronic kidney disease (CKD); Transmembrane protease serine 2 (TMPRSS2).